During a live event, Neal E. Ready, MD, and participants discussed what factors justify using PD-1 plus CTLA-4 inhibitor and ...

When non-small cell lung cancer (NSCLC) spreads beyond the lungs, it often metastasizes to the bones. Estimates suggest 20 to 30 percent of people with NSCLC have bone metastases at the time of ...

Small cells — compact access nodes that can bridge coverage gaps — are a critical piece of 5G networking infrastructure, helping to seamlessly connect a massive number of devices simultaneously. But, ...

A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated ...

A study led by Dana-Farber Cancer Institute researchers found that combining chemotherapy and immunotherapy before surgery ...

The company said the therapy is the first allogenic therapy developed with its Tmod technology to be tested in humans.

The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a ...

The lung-cancer drug Datroway, being jointly developed by AstraZeneca and Daiichi Sankyo, has been approved in the U.S. to treat adult patients with non-small cell lung cancer. "AstraZeneca's Datroway ...

The FDA has granted accelerated approval to datopotamab deruxtecan (Datroway) for adults with locally advanced or metastatic non-small cell lung cancer that carries an EGFR mutation and has progressed ...

Small cell lung cancer is aggressive and spreads quickly. There are many options for treatment, depending on the type and stage of SCLC.

Max Madl, a Brevard Public Schools graduate who ran for school board in 2024, spoke about concerns regarding the proposed ...

AstraZeneca's Datroway drug has been approved in the U.S. to treat adult patients with non-small cell lung cancer. The British pharmaceutical company said Tuesday that the drug has been approved for ...